XKRX
328130
, Last price
KRW
Name
Lunit Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
33.59%
Rev. 5Y
125.36%
Div Yld LY
—
Div Yld TTM
—
Revenues
83.13b
+53.43%
Net income
-46.63b
L-43.43%
CFO
-53.96b
L-17.87%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lunit Inc., established in 2013 and headquartered in Seoul, South Korea, develops and supplies advanced artificial intelligence software solutions aimed at improving cancer screening, diagnosis, and treatment. The company's portfolio includes AI-powered tools for analyzing medical images like chest X-rays and mammograms, as well as intelligent biomarkers for immune phenotyping and precise PD-L1 quantification, which are vital for optimizing immunotherapy.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||